vector vaccine
Showing 1 - 25 of 8,773
COVID-19 Trial (GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition)
Not yet recruiting
- COVID-19
- GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition
- (no location specified)
Oct 4, 2023
COVID-19 Trial (GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile))
Not yet recruiting
- COVID-19
- GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile)
- (no location specified)
Oct 4, 2023
Ebola Virus Trial in Kampala (cAd3-EBO S vaccine)
Completed
- Ebola Virus
- cAd3-EBO S vaccine
-
Kampala, UgandaMakerere University-Walter Reed Project
Nov 10, 2022
SARS-CoV-2 Vaccine in Metabolism-related Fatty Liver Disease
Not yet recruiting
- Metabolic Associated Fatty Liver Disease
- Recombinant protein vaccine and adenovirus vector vaccine
- (no location specified)
Feb 12, 2023
Tuberculosis Infection Trial in Saint Petersburg (TB/Flu-05E vaccine, Placebo)
Active, not recruiting
- Tuberculosis Infection
- TB/Flu-05E vaccine
- Placebo
-
Saint Petersburg, Russian FederationSmorodintsev Research Institute of Influenza
Jul 11, 2023
SARS-CoV-2 Infection Trial in Baltimore (B/HPIV3/S-6P)
Recruiting
- SARS-CoV-2 Infection
- B/HPIV3/S-6P
-
Baltimore, MarylandJohns Hopkins Bloomberg School of Public Health
Aug 30, 2023
Epidemic Meningitis Trial (MCV4)
Not yet recruiting
- Epidemic Meningitis
- MCV4
- (no location specified)
Jul 5, 2023
Marburg Virus Disease Trial in Silver Spring (cAd3-Marburg vaccine)
Completed
- Marburg Virus Disease
- cAd3-Marburg vaccine
-
Silver Spring, MarylandWRAIR Clinical Trials Center,
Aug 9, 2022
Epidemic Meningitis Trial (MCV4, MSPV4)
Not yet recruiting
- Epidemic Meningitis
- MCV4
- MSPV4
- (no location specified)
Aug 21, 2023
COVID-19 Trial in Singapore (Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation)
Not yet recruiting
- COVID-19
- Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation
-
Singapore, SingaporeNational University Hospital
Jan 29, 2023
COVID-19 Trial in Taizhou (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Recombinant Novel Coronavirus
Completed
- COVID-19
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo
-
Taizhou, Jiangsu, ChinaTaixing City center for Disease Control and Prevention
Oct 28, 2022
COVID-19, SARS-CoV-2 Infection Trial in Morelia (Recombinant COVID-19 variant Vaccine (Sf9 Cell), COVID-19 Vaccine (Vero Cell),
Not yet recruiting
- COVID-19
- SARS-CoV-2 Infection
- Recombinant COVID-19 variant Vaccine (Sf9 Cell)
- +3 more
-
Morelia, Michoacán De Ocampo, MexicoClínica de Enfermedades Crónicas y de Procedimientos Especiales,
Jul 18, 2022
COVID-19 Trial (1 Nebulized inhalation for booster groups, 2 Nebulized inhalation for booster groups, 3 Nebulized inhalation for
Recruiting
- COVID-19
- 1 Nebulized inhalation for booster groups
- +23 more
-
Xiangxi, Hunan, ChinaCDC of of Luxi County, Xiangxi Tujia and Miao Autonomous Prefect
Oct 24, 2022
COVID-19 Trial in Yancheng (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml, Recombinant Novel
Active, not recruiting
- COVID-19
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
-
Yancheng, Jiangsu, ChinaFuning Center for Disease Control and Prevention
Oct 28, 2022
COVID-19 Trial in Saint Petersburg (Corfluvec component 1 low dose, Corfluvec component 2 low dose, Corfluvec component 1 high
Active, not recruiting
- COVID-19
- Corfluvec component 1 low dose
- +6 more
-
Saint Petersburg, Russian Federation
- +1 more
Jan 23, 2023
Malaria, Malaria,Falciparum, Protozoan Infections Trial in Sheffield (Matrix M with RH5.1)
Recruiting
- Malaria
- +5 more
- Matrix M with RH5.1
-
Sheffield, United KingdomSheffield Teaching Hospitals, Royal Hallamshire Hospital
Nov 14, 2023
Participants in Preventive HIV Vaccine Studies in Uganda
Completed
- HIV Infections
-
Kampala, UgandaMakerere University Walter Reed Project (MUWRP)
Oct 28, 2021
COVID-19 Trial (Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector), Bivalent Recombinant COVID-19 Vaccine
Not yet recruiting
- COVID-19
- Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)
- +2 more
- (no location specified)
Jul 5, 2022
HIV Trial (VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP, VRC-HIVDNA016-00-VP )
Withdrawn
- HIV Infections
- VRC-HIVDNA016-00-VP
- +3 more
- (no location specified)
Oct 28, 2021
Herpes Zoster Trial in Halifax (Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV), Zoster Vaccine Recombinant,
Not yet recruiting
- Herpes Zoster
- Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV)
- +5 more
-
Halifax, CanadaCanadian Center for Vaccinology
Aug 6, 2023
COVID-19, SARS-CoV-2 Acute Respiratory Disease Trial (Gam-COVID-Vac, Placebo)
Not yet recruiting
- COVID-19
- SARS-CoV-2 Acute Respiratory Disease
- Gam-COVID-Vac
- Placebo
- (no location specified)
Mar 7, 2022
Covid19 Trial in Cypress (VXA-CoV2-1)
Completed
- Covid19
- VXA-CoV2-1
-
Cypress, CaliforniaWCCT
Jan 17, 2023
Malaria, Malaria,Falciparum, Parasitic Disease Trial in Oxford (RH5.1 and/or RH5.2-VLP with Matrix-M)
Not yet recruiting
- Malaria
- +4 more
- RH5.1 and/or RH5.2-VLP with Matrix-M
-
Oxford, Oxfordshire, United KingdomCentre for Clinical Vaccinology & Tropical Medicine (CCVTM)
Jul 27, 2023
COVID-19 Trial in Al Ain (AZD1222, rAd26-S)
Completed
- COVID-19
- AZD1222
- rAd26-S
-
Al Ain, United Arab EmiratesTawam Hospital
Oct 24, 2022
COVID-19 Trial in Nanjing (recombinant Ad5 vectored COVID-19 vaccine, RBD-based protein subunit vaccine (ZF2001) against
Completed
- COVID-19
- recombinant Ad5 vectored COVID-19 vaccine
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Provincial Center for Diseases Control and Prevention
Mar 28, 2022